Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Purpose Transforming growth factor-beta (TGF-[beta]) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-[beta] signaling reverse EMT and arrest tumor progression. Several SMIs were developed, but c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2015-04, Vol.33 (2), p.357
Hauptverfasser:	Rodón, Jordi, Carducci, Michael, Sepulveda-sánchez, Juan M, Azaro, Analía, Calvo, Emiliano, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Gueorguieva, Ivelina, Cleverly, Ann, Pillay, N Sokalingum, Desaiah, Durisala, Estrem, Shawn T, Paz-ares, Luis, Holdhoff, Matthias, Blakeley, Jaishri, Lahn, Michael M, Baselga, Jose
Format:	Artikel
Sprache:	eng
Schlagworte:	Bioavailability Biomarkers Cancer therapies Drug dosages Drug therapy Enzymes Glioma Growth factors Kinases Ligands Medical research Mutation Oncology Patients Pharmacodynamics Pharmacokinetics Plasma Proteins Statistical analysis TNF inhibitors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!